Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50: 31/3500 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 96.00 | |
10 mg | In stock | $ 129.00 | |
25 mg | In stock | $ 293.00 | |
50 mg | In stock | $ 492.00 | |
100 mg | In stock | $ 688.00 | |
500 mg | In stock | $ 1,430.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 98.00 |
Description | Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50: 31/3500 nM). |
Targets&IC50 | 20S proteasome:0.93 nM(Ki), 20S proteasome:3.4 nM, Caspase-like β1:31nM, Trypsin like β2:3500 nM |
Kinase Assay | Kinase assay : Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
Cell Research | Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium. (Only for Reference) |
Synonyms | MLN2238 |
Molecular Weight | 361.03 |
Formula | C14H19BCl2N2O4 |
CAS No. | 1072833-77-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 67 mg/mL (185.6 mM)
Ethanol: 9 mg/mL (24.92 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ixazomib 1072833-77-2 Apoptosis Autophagy Proteases/Proteasome Ubiquitination Proteasome Caspase Inhibitor MLN2238 MLN-2238 MLN 2238 inhibit inhibitor